Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN)

Koto, Masashi; Demizu, Yusuke; Saitoh, Jun‐ichi; Suefuji, Hiroaki; Tsuji, Hiroshi; Okimoto, Tomoaki; Ohno, Tatsuya; Shioyama, Yoshiyuki; Takagi, Ryo; Nemoto, Kenji; Nakano, Takashi; Kamada, Tadashi

doi:10.1016/j.ijrobp.2016.12.028

Cited by 97 publications

(89 citation statements)

References 25 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study included 19 patients (66%) who received concurrent chemotherapy, including DTIC, which did not significantly improve prognosis based on 5‐year rates of 87.4% for local control and 48.8% for OS. Nevertheless, a retrospective multicenter study of C‐ion RT for head and neck mucosal melanoma revealed that a survival benefit was associated with concurrent chemotherapy, including DTIC . Moreover, complementary activity against melanoma has recently been reported for ipilimumab (a cytotoxic T‐lymphocyte‐associated antigen‐4 checkpoint inhibitor) and nivolumab (a programmed death‐1 checkpoint inhibitor), and Karlsson et al have reported that checkpoint inhibitors are more effective than immunotherapy or chemotherapy in terms of survival and tumor response among patients with stage III/IV unresectable cutaneous melanoma .…”

Section: Discussionmentioning

confidence: 99%

“…Carbon ion RT (C‐ion RT) has a higher linear energy transfer and a greater relative biological effectiveness (RBE) than photon RT . Furthermore, various reports have described promising results from C‐ion RT for radioresistant tumors, such as salivary gland carcinoma (SGC) and mucosal melanoma of the head and neck . Koto et al evaluated 46 patients with locally advanced parotid gland carcinoma who were followed‐up for a median of 62 months and reported 5‐year rates of 74.5% for local control and 70.1% for overall survival (OS).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Feasibility of carbon‐ion radiotherapy for oral non‐squamous cell carcinomas

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background This study evaluated carbon‐ion radiotherapy (C‐ion RT) for oral non‐squamous cell carcinomas (non‐SCC). Methods We retrospectively obtained data from 74 patients who underwent C‐ion RT for oral malignancies between April 1997 and March 2016. The C‐ion RT was administered in 16 fractions at a total dose of 57.6 or 64.0 Gy (relative biological effectiveness). Results Forty‐three patients had salivary gland carcinomas, 29 patients had mucosal melanoma, and 2 patients had other types of pathologies. The tumors were classified as T1‐T3 (24 cases), T4a (21 cases), or T4b (29 cases). The median follow‐up was 49 months. The 5‐year rates were 78.8% for local control, 36.2% for progression‐free survival, and 58.3% for overall survival. Although 10 patients developed grade 3 osteoradionecrosis after C‐ion RT, all patients maintained their mastication and deglutition functions after sequestrectomy and prosthesis placement. Conclusion C‐ion RT was effective for oral non‐SCC and had acceptable toxicities.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Feasibility of carbon‐ion radiotherapy for oral non‐squamous cell carcinomas

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, adjuvant postoperative radiation therapy may improve locoregional control but does not appear to affect survival . Although mucosal melanomas are known to be radioresistant, a recent retrospective multicenter study showed that carbon ion radiation therapy resulted in good local control and overall survival with acceptable toxicities . Complete surgical excision with clear margins is one of the most important prognostic factors .…”

Section: Discussionmentioning

confidence: 99%

Synergistic effects of interferon‐beta and nivolumab in oral mucosal melanoma

Fusumae

Chiang

Okada

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

Mucosal melanoma is a rare aggressive cancer with a very poor prognosis. Clinical and pathological characteristics of mucosal melanoma differ from those of cutaneous melanoma and there are no established management guidelines for mucosal melanoma. Complete surgical excision is one of the most effective treatments for localized lesions, while targeted therapies and immunotherapies, such as monoclonal antibodies that target cytotoxic T-lymphocyte-associated molecule-4, and the programmed death (PD)-1/PD-ligand 1 pathway inhibitors, are treatment options for unresectable or metastatic lesions. Here, we describe the case of a patient with oral mucosal melanoma with multiple metastases. In our case, local injection of interferon (IFN)-b with dacarbazine-nimustinevincristine therapy provided antitumor effects on an invasive tumor on the upper gingiva. Nivolumab therapy produced complete remission of lymph node and bone metastases. In contrast, the remaining in situ portion of oral mucosal melanoma on the hard palate was refractory to IFN-b monotherapy and nivolumab therapy. However, after administration of nivolumab, peritumoral injection of IFN-b showed rapid therapeutic effects. Our case suggested that nivolumab upregulated the antitumor effects of IFN-b, which induced the recruitment of CD8 + T cells into the tumor microenvironment contributing to the deletion of tumor cells. Combination therapy of IFN-b and nivolumab may be a potential treatment option for patients with oral mucosal melanoma.

show abstract

“…Patients suffering from head and neck malignancies and treated with C‐ion RT between November 2003 and December 2014 were included. Detailed inclusion criteria have been described previously . Patients with previous irradiation to the head and neck were excluded.…”

Section: Methodsmentioning

confidence: 99%

“…A retrospective multicenter study to evaluate the clinical outcomes of C‐ion RT for head and neck malignancies was performed (Japan Carbon‐Ion Radiation Oncology Study Group [J‐CROS] Study: 1402 HN). The clinical outcomes of the respective major histological types of head and neck malignancies have already been reported . The 5‐year local control and overall survival (OS) rates among patients with adenoid cystic carcinoma, mucosal melanoma, and adenocarcinoma of 68% and 74%, 72.3% and 44.6%, and 79.3% and 60.4%, respectively, were also reported …”

Section: Introductionmentioning

confidence: 98%

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background The aim of this study was to evaluate the efficacy and safety of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity in a multicenter study. Methods Retrospective analysis of the clinicopathological features and outcomes of 76 patients with oral nonsquamous cell carcinomas with N0‐1 M0 status and were treated with carbon‐ion radiation therapy at four institutions in Japan between November 2003 and December 2014 was performed. Results Salivary gland carcinoma, mucosal melanoma, and three other carcinomas were found in 46, 27, and 3 patients, respectively. T1‐3, T4a, and T4b disease was diagnosed in 27, 18, and 31 patients, respectively. Median follow‐up period was 31.1 months (range, 3‐118 months). Three‐year local control, progression‐free survival, and overall survival of all patients were 86.8%, 63.1%, and 78.4%, respectively. Multivariate analysis showed T classification (T4) to be a significant independent poor prognostic factor for local control. Acute grade 3 mucositis was observed in 38 patients. Grades 3 and 4 late morbidities were observed in 9 and 4 patients, respectively. No grade 5 late toxicity was observed. Conclusions Oral nonsquamous cell carcinomas could be treated effectively, with acceptable toxicity, by carbon‐ion radiation therapy.

show abstract

Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN)

Abstract: Carbon-ion RT is a promising treatment option for MMHN.

Cited by 97 publications

References 25 publications

Feasibility of carbon‐ion radiotherapy for oral non‐squamous cell carcinomas

Feasibility of carbon‐ion radiotherapy for oral non‐squamous cell carcinomas

Synergistic effects of interferon‐beta and nivolumab in oral mucosal melanoma

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity

Contact Info

Product

Resources

About